High Throughput Screening for identifying effective immuno-modulators.
- HT screening platform replicating complex immune medicated response to facilitate the discovery of small molecule immunomodulatory agents.
- Simplicity and dual readouts of the design enable the screening of large chemical libraries to identify compounds that stimulate or potentiate immune cells to attack cancer cells.
The global market for drug discovery technologies was $69.8 billion in 2020 and is expected to grow to $110.4 billion by 2025 with a CAGR of 9.6% 2020-2025. The expected second highest market in the drug discovery market is high throughput screening (HST). The global HST market in 2020 was $12.8 billion and is expected to reach $20.1 billion by 2025 with a CAGR of 9.4% from 2020-to 2025 (BCC Research BIO020G). Market expansion is supported by innovation in techniques including high throughput techniques for phenotypic profiling of compounds based on changes in cellular activity.
The lack of HT (High Throughput) screening platforms that replicate the complexity of the immunosuppressive nature of cancer cells has delayed the discovery of such compounds. Researchers at Emory have developed an HTiP (High-Throughput immunomodulator Phenotypic) screening platform with the purpose of facilitating the identification of effective small molecule immune-modulators from a larger chemical compound library. The screening platform provides a vigorous ex-vivo tumor environment which reflects the immune response network by co-culturing cancer cells with PBMCs (human peripheral blood mononuclear cells). This PBMCS contains a mixture of dendritic cells, monocytes, and lymphocytes.
TTO Home Page: https://emoryott.technologypublisher.com
Name: Hyeon (Sean) Kim
Title: Licensing Associate